|
|
-Review-
Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease
1Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan
2Division of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis and hepatocellular carcinoma. Interferon-based treatment was previously the only antiviral therapy for chronic hepatitis C infection; however, development of interferon-free, direct-acting antivirals, in 2014, markedly improved treatment efficacy and safety. Treatment indications were expanded to include elderly adults, patients with advanced liver fibrosis, and patients with chronic hepatitis C infection complicated by chronic kidney disease, for whom antiviral therapy had been difficult or contraindicated. The median age of patients with chronic HCV infection in Japan is 70 years, older than in other countries. Because diminished renal function is common in elderly adults, a safe and effective treatment for chronic hepatitis C complicated by chronic kidney disease has been expected in Japan. In addition, the HCV antibody-positive rate is higher in hemodialysis patients than in non-hemodialysis patients in Japan. Numerous studies have reported that direct-acting antivirals are safe and effective for hepatitis C patients on hemodialysis. This review summarizes treatments available in Japanese clinical practice for patients with chronic HCV infection complicated by chronic kidney disease, including hemodialysis patients.
J Nippon Med Sch 2021; 88: 163-170
Keywords
chronic hepatitis C, direct-acting antivirals, chronic kidney disease
Correspondence to
Masanori Atsukawa, Division of Gastroenterology and Hepatology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan
gachi@nms.ac.jp
Received, October 11, 2020
Accepted, February 3, 2021
PDF (81K)